Search Results 1951-1960 of 17073 for monoclonal antibody

1. Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma - Mayo Clinic

   < 4 weeks for immunotherapy or antibody therapy. Participants must have recovered (≤ Grade 2 or at pretreatment baseline) from AEs from previously ...

2. Safety of MT-401-OTS in Patients with Relapsed AML or MDS - Mayo Clinic

   ... antibodies to total anti-HBc with or without the presence of anti-HBs) must be screened using RT-PCR measurement of HBV DNA levels. Those who are RT PCR ...

3. A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects - Mayo Clinic

   0 Grade 4 immune-related AE due to adjuvant CTLA-4 or PD-1 blocking antibody. Not fully recovered from adverse events (to Grade 1 or less [per CTCAE v5.0] ...

4. A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis - Mayo Clinic

   antibody - Study participant must have ≥ 2 seizures/week during the Screening Period or have experienced such seizures that stopped following high dose ...

5. Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma - Mayo Clinic

   Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA ...

6. T Cell Response to COVID19 Vaccinated Individuals - Mayo Clinic

   The third aim is to measure SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies to distinguish patients that have not been exposed to SARS-CoV-2 to those ...

7. Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT) - Mayo Clinic

   Subjects with unknown HIV status should be tested for HIV antibodies per standard of care. 20. Pregnant or lactating females. 21. The Principal Investigator ...

8. MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer - Mayo Clinic

   Must have anti-measles immunity as demonstrated by serum IgG anti-measles antibody levels of ≥ 1.1 EU/ml as determined by BioPlex Measles IgG multiplex flow ...

9. Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia - Mayo Clinic

   History of anti-drug antibody formation 19. History of inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or have ...

10. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) - Mayo Clinic

    * Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC). * Received prior treatment with a ...